Alkermes PLC
Suletud
SektorTervishoid
45.82 -0.54
Ülevaade
Aktsiahinna muutus
24h
Min
45.62
Max
46
Sissetulek | 67M 501K |
|---|---|
Müük | 103M 496M |
P/E Sektori keskmine | 121.316 56.597 |
Aktsiakasum | 0.52 |
Kasumimarginaal | 0.101 |
Töötajad | 2,050 |
EBITDA | 76M 54M |
Järgmine tulemuste avaldamine | 27. okt 2026 |
|---|
Turukapital | -1.1B 7.7B |
|---|---|
Eelmine avamishind | 46.36 |
Eelmine sulgemishind | 45.82 |
Uudiste sentiment
By Acuity
50%
50%
126 / 339 Pingereas Healthcare
Alkermes PLC Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Alkermes PLC Prognoos
Sentiment
By Acuity
126 / 339 Pingereas Tervishoid
Uudiste sentiment
Neutral
Volatiilsus
Alla keskmise
Uudismaht (RCV)
Alla keskmise
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Alkermes PLC
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.